ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $12.00

ProQR Therapeutics (NASDAQ:PRQR) had its price target upped by HC Wainwright from $10.00 to $12.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the stock. Chardan Capital reissued a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday. Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Monday, March 10th. Oppenheimer began coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price on the stock. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, JMP Securities reissued a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $1.69 on Friday. The company has a 50 day simple moving average of $2.25 and a 200-day simple moving average of $2.62. ProQR Therapeutics has a 52-week low of $1.61 and a 52-week high of $4.62. The firm has a market capitalization of $138.04 million, a price-to-earnings ratio of -5.28 and a beta of 0.24.

Institutional Trading of ProQR Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alpine Global Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $39,000. Woodline Partners LP bought a new stake in ProQR Therapeutics during the fourth quarter worth approximately $9,426,000. Velan Capital Investment Management LP bought a new position in shares of ProQR Therapeutics in the fourth quarter valued at approximately $107,000. Squarepoint Ops LLC raised its position in shares of ProQR Therapeutics by 16.3% in the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 11,623 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of ProQR Therapeutics by 512.8% in the fourth quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 320,614 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).